In a remote monitoring workflow where 80% of transmissions are benign, treating all transmissions as equal review items is not just inefficient — it is clinically suboptimal. The coordinator who spends the same amount of review time on a routine scheduled transmission from a patient with a two-year stable AF burden history as on a transmission from a patient whose AF burden has doubled over the past 60 days is not practicing equivalently. One review is confirmatory; the other is clinical decision support for a potential management change. Risk stratification is the framework for distinguishing the two before the coordinator begins.
Risk stratification in EP clinic remote monitoring is not the same as risk stratification in acute cardiac care. It does not identify who is about to have a sudden cardiac event. It identifies which transmissions, given the full clinical context of the patient, are likely to require action — a physician communication, a medication adjustment, a visit acceleration, or a documentation update beyond a standard note. The output of the stratification process is a priority tier for the transmission, not a clinical diagnosis.
The inputs to that stratification should include at minimum: the patient's implant indication, their current antiarrhythmic medications, their documented monitoring thresholds, the contents of the current transmission, and the patient's recent monitoring history. The combination of these inputs, not any single input alone, determines the likely action requirement for a given transmission.
The implant indication establishes a baseline monitoring priority for each patient independent of any specific transmission. A patient implanted for cryptogenic stroke with no prior AF detection is a high-priority review patient by definition, because the clinical question their device is answering — is there occult AF that would justify anticoagulation? — is an active, unresolved question with significant treatment implications. Any AF detection above the minimum duration threshold in this patient requires physician review regardless of burden percentage.
A patient implanted for palpitations evaluation who has had three prior transmissions confirming sinus tachycardia correlated with exertion, with the physician having documented "likely inappropriate sinus tachycardia, monitoring ongoing," is a lower baseline priority for subsequent scheduled transmissions showing the same finding. The clinical question is still open, but the finding is no longer new information.
Building indication-based baseline priorities into the review workflow requires that the monitoring system has access to the implant indication and can incorporate it into the queue presentation. Most manufacturer platforms do not do this natively; the indication appears in the patient's device account record but does not influence transmission queue sorting.
The single most important variable in remote monitoring risk stratification is whether a finding is new relative to the patient's documented history. An AF burden of 4.2% in a patient whose prior six transmissions showed 3.8%, 4.1%, 3.9%, 4.0%, 4.3%, and 3.7% is baseline. The same 4.2% in a patient whose prior six transmissions showed 0.0% across all metrics is a new finding requiring escalation regardless of the absolute value.
This is why history-relative assessment requires access to the monitoring history, not just the current transmission. A review system that shows only the current transmission AF burden without context allows the coordinator to look up prior transmissions manually, but it does not surface the comparison automatically. The coordinator who is working through a 60-item queue under time pressure is unlikely to pull six prior transmissions for every item to perform the comparison manually. The risk is that stable-but-elevated chronic findings receive the same escalation behavior as genuinely new findings of the same absolute value.
Within a risk stratification framework, certain characteristics predictably increase the likelihood that a transmission requires action:
The opportunity cost of undifferentiated review is not abstract. A coordinator who cannot distinguish high-priority from low-priority transmissions before starting review will, under time pressure, make that distinction implicitly — based on factors that should not matter, like which item appears at the top of the queue or which patient name is familiar. Formalized risk stratification replaces that implicit triage with an explicit, reproducible one based on clinical criteria.
Implansense's clinical-context risk stratifier generates a priority score for each incoming transmission based on the factors described above — indication, threshold calibration, finding type, history comparison, and transmission type. The coordinator's queue is presented in priority order, with high-priority transmissions at the top and their priority rationale displayed. Transmissions that are routine benign based on all available context are grouped at the bottom with pre-staged documentation templates. The coordinator's attention is directed before the review begins, not after working through the full queue.
Risk stratification does not reduce the clinical responsibility of the reviewing coordinator. What it does is ensure that clinical attention is allocated proportionally to clinical need, which is what good medical practice requires and what undifferentiated high-volume review makes increasingly difficult to achieve.
